Litigation Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Limited (D. Del. 2019)

Boehringer Ingelheim Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Limited (D. Del. 2019)

Docket		Date Filed	2019-08-09
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Parties	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Patents	10,258,637
Attorneys	John C. Phillips , Jr.
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Limited (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-08-09				External link to document

Litigation summary and analysis for: Boehringer Ingelheim Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Limited (D. Del. 2019)

Last updated: June 17, 2026

Boehringer Ingelheim v. Sun (1:19-cv-01500): Litigation Summary, Patent Issues, Timeline, and Generic-Entry Impact

Boehringer Ingelheim Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Ltd. (D. Del., 1:19-cv-01500) is a Hatch-Waxman patent infringement dispute tied to Sun’s FDA Abbreviated New Drug Application (ANDA) challenge. The case fits the Paragraph IV framework in which the ANDA filer seeks approval to market a generic before expiration of listed patents. This litigation summary sets out the procedural posture, what the case typically turns on in this posture (claims, listed Orange Book patents, and the “artificial” merits window created by statutory deadlines), and the commercial/legal consequence for generic entry timing.

What is Boehringer Ingelheim Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Limited (1:19-cv-01500) about?

The matter is a U.S. patent infringement action filed in federal court by Boehringer Ingelheim Pharmaceuticals Inc. against Sun Pharmaceutical Industries Limited, docketed as 1:19-cv-01500. The dispute is structured as an ANDA-driven Paragraph IV litigation, where Boehringer asserts that Sun’s proposed generic infringes one or more Orange Book-listed patents for the relevant branded product and/or formulation or method of use.

Is this an ANDA Paragraph IV case?

Yes, the case posture aligns with Hatch-Waxman Paragraph IV infringement suits brought against ANDA applicants. Those suits are designed to adjudicate, on a compressed timeline, whether the asserted patents are infringed and not invalid, which affects whether FDA can approve the ANDA and whether a 180-day exclusivity “slot” attaches to a Paragraph IV filer.

What patents typically drive these actions?

In Paragraph IV frameworks like this one, the asserted estate usually includes one or more of:

• Drug substance or composition of matter patents
• Formulation patents (e.g., dosage form compositions, stability, excipient systems)
• Method-of-use patents
• Manufacturing or process patents

The litigation’s practical objective is to obtain a judgment that preserves the brand’s market exclusivity by blocking FDA approval until patent expiry or by securing an injunction against launch.

What is the procedural timeline for 1:19-cv-01500?

The case number indicates a filing in 2019 in the U.S. District Court, District of Delaware. The procedural timeline in such Paragraph IV cases typically follows a predictable cadence:

• Complaint filed after FDA acceptance of an ANDA with a Paragraph IV certification
• Answer and infringement claim framing
• Early scheduling orders for claim construction
• Claim construction (Markman)
• Summary judgment or dispositive motions
• Trial or stipulations
• Potential appellate review if judgment issues

What deadlines matter commercially?

• FDA approval timing is constrained by statutory 30-month stay rules that attach after a Paragraph IV notice and infringement filing.
• Patent expiry (listed in the Orange Book) can end the litigation’s practical value if the asserted patents expire before final judgment.
• Design-around and non-infringement arguments often turn on whether Sun’s formulation or labeling stays inside or outside the asserted claim boundaries.

Which patents are asserted in Boehringer v. Sun (1:19-cv-01500)?

The key infringement issue in Paragraph IV litigation is identification of the asserted Orange Book patents and the mapping of Sun’s product to those claim elements. Patent-specific details (publication numbers, claim sets, and asserted patents’ expiration dates) are central to any infringement and validity analysis.

Litigation consequence depends on patent type

• Composition-of-matter / drug substance: strongest barriers to generic entry.
• Formulation: risk concentrates on excipient systems, particle properties, or solid-state parameters tied to claim limitations.
• Method-of-use: can be avoided through labeling changes, but courts can still find infringement if the generic’s “intended use” or instructions trigger the patented method.
• Process patents: can be avoided if manufacturing steps differ, but discovery-heavy issues frequently arise.

How does 1:19-cv-01500 typically analyze infringement in an ANDA context?

Paragraph IV cases proceed on a two-track logic:

1. Infringement: whether Sun’s “proposed product” (as described in the ANDA) would infringe asserted claims.
2. Validity/unenforceability: whether asserted claims fail on novelty, obviousness, lack of written description/enablement, indefiniteness, or other defenses.

What claim features drive infringement outcomes?

In practice, infringement in this posture hinges on:

• precise claim language (e.g., dosage form constraints, compositional ranges, or method steps),
• the ANDA’s described manufacturing and formulation,
• expert testimony on equivalence vs. literal claim boundaries,
• and whether the relevant regulatory labeling induces the patented use.

What defenses does a Sun-type ANDA filer typically raise?

Typical defenses in this genre include:

• Non-infringement: proposed generic does not meet every claim limitation.
• Invalidity: prior art anticipation/obviousness against the asserted claims.
• Indefiniteness: claim language does not reasonably inform those skilled in the art.
• Written description/enablement: specification does not support full claim scope.

Because the case is ANDA-linked, discovery and expert work often center on the ANDA’s formulation and the brand’s patent record.

When does the generic launch risk materialize for Boehringer v. Sun?

Commercially, “launch risk” moves based on:

• injunction outcomes (if the court issues or denies injunctive relief),
• entry approvals by FDA after statutory stays,
• expiration of asserted patents (Orange Book dates),
• and whether appeal stays the injunction.

Key launch milestones that matter

• 30-month stay expiration or lifting: impacts whether FDA approval can occur.
• Final judgment on patent validity/infringement: sets whether FDA can approve and whether launch triggers infringement exposure.
• Settlement agreements: often control timing even when patents are contested.

Did the parties settle 1:19-cv-01500, and what does settlement usually mean?

Settlement in Paragraph IV cases typically produces:

• Date-certain non-launch commitments by the ANDA applicant
• License agreements under which the generic may be permitted to launch at an agreed time
• Dismissal of claims in exchange for a covenant not to sue and commercial terms

In many brand/generic arrangements, the settlement moves the dispute from “court risk” to “contract risk,” with launch conditions tied to specified regulatory and patent events.

What is the Orange Book status implication for the parties in 1:19-cv-01500?

Orange Book status is the hinge between litigation and FDA action. Orange Book-listed patents are the patents that drive certification-driven litigation. The practical implications are:

• If asserted patents expire during the pendency of the action, the scope of remaining relief shrinks.
• If the brand narrows its asserted claims or stipulates non-infringement, the remaining patent coverage contracts.
• If the court invalidates or finds non-infringement, FDA approval can proceed subject to other stays or unasserted patents.

What is the strength of the Boehringer patent estate in disputes like 1:19-cv-01500?

Patent estate strength in this litigation style is measured by:

• number of listed patents asserted,
• how many claims are independently infringed,
• and whether validity defenses are likely to defeat the core claims.

In high-value brand products, multiple patents often create redundancy. Even if one patent fails, other patents can still block entry via remaining asserted or unasserted Orange Book listings.

How does Boehringer’s case strategy compare with other brand Paragraph IV litigations?

Brand plaintiffs usually focus on:

• early claim construction to lock claim scope,
• expert-driven infringement theories built on ANDA descriptions,
• and invalidity rebuttal with secondary considerations and patent prosecution history.

ANDA defendants typically focus on:

• tight non-infringement mapping,
• prior-art invalidity,
• and procedural motions to narrow asserted claims early.

What generic entry risks exist for Sun if it loses 1:19-cv-01500?

If Boehringer prevails on infringement and validity:

• FDA approval can still be constrained by other listed patents not addressed by the case.
• Launch would carry high infringement risk, unless the defendant carves out a design-around or changes label/implementation outside the claim boundaries.
• The defendant’s leverage shifts to settlement or appeal rather than immediate approval.

What biosimilar risk applies here?

This action is in the “small-molecule ANDA” universe implied by the docket caption (FDA ANDA Paragraph IV suits). Biosimilar-specific doctrines do not typically apply unless the product is biologic and the case is an “351(k)” biosimilar action, which is not the posture indicated by the case name and filing style.

Commercial impact: what does this litigation do to Boehringer and Sun revenue exposure?

For Boehringer:

• a favorable outcome extends exclusivity by preventing or delaying generic market entry,
• protecting royalty or settlement leverage.

For Sun:

• litigation outcome determines when it can market its generic and whether it must pay into a settlement structure,
• affects the timing of investment in supply chain readiness and launch marketing.

Key takeaways on 1:19-cv-01500

• The case is a Hatch-Waxman Paragraph IV infringement action filed in the District of Delaware in 2019.
• The litigation’s core drivers are infringement mapping to Orange Book-listed patents and validity defenses tied to prior art and claim scope.
• Commercially, the outcome controls whether FDA approval and generic launch are blocked, delayed, or permitted via settlement or patent expiry.

---

FAQs

1. What is a Paragraph IV certification and how does it relate to 1:19-cv-01500?
   It is the ANDA applicant’s legal statement that the Orange Book patents are invalid and/or not infringed, which triggers a patent infringement suit and can delay FDA approval.

2. How do 30-month stays affect generic approval in ANDA litigation like Boehringer v. Sun?
   The automatic stay can delay FDA approval until it expires or is lifted by a court ruling or other statutory event.

3. What happens if the asserted patents expire during a pending Paragraph IV case?
   The practical need for an injunction can diminish, and courts often address mootness or remaining counts, though residual damages or other patents can remain.

4. How can a generic avoid method-of-use patent claims without changing the drug?
   Through labeling carve-outs that remove instructions or indications that induce the patented method, subject to “intended use” and inducement analyses.

5. Does winning or losing affect only one patent in a typical Orange Book estate?
   Not necessarily. Courts adjudicate asserted patents, but other unasserted listed patents can still block FDA approval and launch.

---

References

1. Boehringer Ingelheim Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Limited, No. 1:19-cv-01500 (D. Del.).